Expertise in
5
conditions

Dr. Richard K. Valicenti

Radiology | Radiation Oncology
3850 G St, 
Merced, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
5
conditions
3850 G St, 
Merced, CA 

Overview

Richard Valicenti is a Radiologist and a Radiation Oncologist practicing medicine in Merced, California.

Dr. Valicenti is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Cervical Cancer, and Prostatectomy.

Dr. Valicenti is board certified in Radiology Radiation Oncology. He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 11 clinical trials. Dr. Valicenti is currently accepting new patients.

Specialties

Radiology
Radiation Oncology

Licenses

Radiology in PA

Board Certifications

Radiology Radiation Oncology

Fellowships

Washington University School of Medicine

Hospital Affiliations

Banner Lassen Medical Center
Marshall Medical Center
University Of California Davis Medical Center
Adventist Health And Rideout

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Mercy Cancer Center
3850 G St, Merced, CA 95340

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Radiation
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
View 9 Less Clinical Trials

47 Total Publications

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.
Journal: JCO precision oncology
Published: July 08, 2026
Similar Doctors
Expertise in
37
conditions
Dr. Ruben C. Fragoso
Radiology | Radiation Oncology
Expertise in
37
conditions
Dr. Ruben C. Fragoso
Radiology | Radiation Oncology
Referral may be required
Before you request

Mercy Cancer Center

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-564-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Fragoso is a Radiologist and a Radiation Oncologist practicing medicine in Merced, California. Dr. Fragoso is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Meningioma, Astrocytoma, Radiation Induced Meningioma, and Glioblastoma. Dr. Fragoso is board certified in Radiology Radiation Oncology. Dr. Fragoso is currently accepting new patients.

Expertise in
18
conditions
Dr. Arta M. Monjazeb
Radiology | Radiation Oncology
Expertise in
18
conditions
Dr. Arta M. Monjazeb
Radiology | Radiation Oncology
Referral may be required
Before you request

Arta M. Monjazeb, MD Private Practice

Mercy Cancer Center, 3850 G St, 
Merced, CA 
 (2.5 miles away)
209-564-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arta Monjazeb is a Radiologist and a Radiation Oncologist practicing medicine in Merced, California. Dr. Monjazeb is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Anal Cancer, and Angiosarcoma. Dr. Monjazeb is board certified in Radiology Radiation Oncology. Dr. Monjazeb is currently accepting new patients.

Expertise in
12
conditions
Dr. Megan E. Daly
Radiation Oncology
Expertise in
12
conditions
Dr. Megan E. Daly
Radiation Oncology
Referral may be required
Before you request

Megan E. Daly, MD Private Practice

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-564-3601
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Megan E. Daly is a board-certified UCI Health radiation oncologist.She earned her medical degree and completed a residency in radiation oncology at Stanford University School of Medicine. Dr. Daly is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Microvascular Decompression. Dr. Daly is board certified in American Board Of Radiology - Radiation Oncology and Radiology Radiation Oncology. Dr. Daly is currently accepting new patients.

Frequently Asked Questions about Dr. Richard K. Valicenti

How do I make an appointment with Dr. Richard K. Valicenti?

You can book an appointment with Dr. Richard K. Valicenti by calling their office at 209-564-3600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard K. Valicenti a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard K. Valicenti is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard K. Valicenti specialize in?

While Dr. Richard K. Valicenti is a Radiology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiology.

Does Dr. Richard K. Valicenti participate in research or clinical trials?

Yes. Dr. Richard K. Valicenti has published 47 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Richard K. Valicenti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Richard K. Valicenti accept my insurance?

Dr. Richard K. Valicenti accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 209-564-3600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Valicenti's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile